RefleXion Achieves Broader Medicare Reimbursement Approval for SCINTIX Cancer Therapy
RefleXion Medical has announced a significant advancement in reimbursement support for its innovative SCINTIX® autonomous radiotherapy platform, as Noridian Healthcare Solutions, LLC has established payment rates for the therapy in freestanding centers (FSCs) across its jurisdictions. This latest decision represents an important step forward in expanding access to advanced cancer treatment options for Medicare beneficiaries and further validates the clinical and economic value of SCINTIX therapy.
The reimbursement determination by Noridian follows similar actions taken by other Medicare Administrative Contractors (MACs), which had previously set payment levels for SCINTIX therapy in multiple jurisdictions across the southern and eastern United States. Notably, those earlier decisions established reimbursement rates above those associated with conventional radiotherapy, reflecting the advanced nature of the SCINTIX platform and the additional resources required for its delivery. With Noridian now joining this group, more than half of U.S. states and territories are covered by MACs that recognize and support the value of this next-generation radiotherapy approach.
Medicare Administrative Contractors play a critical role in the U.S. healthcare system by processing claims and determining reimbursement policies for services provided to Medicare beneficiaries. Their decisions can significantly influence the adoption of new medical technologies, particularly in oncology, where treatment costs and reimbursement structures are key considerations for healthcare providers. By establishing favorable payment rates for SCINTIX therapy, Noridian has effectively reduced a major barrier that might otherwise limit its use in clinical practice.
Todd Powell, President and Chief Executive Officer of RefleXion Medical, emphasized the importance of this development, noting that reimbursement clarity is essential for both providers and patients. He highlighted that the decision not only facilitates broader patient access but also provides reassurance to freestanding center operators who are considering the integration of innovative technologies into their treatment offerings. According to Powell, the growing alignment among MACs in supporting SCINTIX therapy underscores its potential to transform cancer care delivery in community-based settings.
The impact of Noridian’s decision is substantial in terms of geographic reach. The contractor’s jurisdictions include 16 states and U.S. territories: Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming, as well as American Samoa, Guam, and the Northern Mariana Islands. This expansion significantly increases the number of Medicare patients who may now have access to SCINTIX therapy, particularly in regions where access to cutting-edge cancer treatments has historically been more limited.
Freestanding centers play a vital role in the delivery of radiation therapy in the United States. It is estimated that more than 40 percent of U.S. cancer patients receive radiation treatment in these outpatient settings. Unlike hospital-based facilities, FSCs often operate with tighter financial margins and must carefully evaluate the cost-effectiveness of adopting new technologies. As a result, reimbursement decisions such as Noridian’s are crucial in enabling these centers to offer advanced therapies without incurring unsustainable financial risk.
SCINTIX therapy represents a novel approach to radiotherapy that integrates advanced imaging and treatment delivery in a highly automated system. A key component of the therapy is a pre-treatment process known as functional modeling. This step involves the use of imaging data to identify and map cancerous lesions throughout the body, allowing for highly personalized treatment planning. Following this modeling phase, patients typically undergo up to five treatment sessions, during which radiation is precisely delivered to targeted tumor sites.
One of the distinguishing features of SCINTIX therapy is its ability to track and treat multiple tumors in real time, potentially improving treatment accuracy and efficiency. This capability may be particularly beneficial for patients with metastatic disease, where cancer has spread to multiple locations and requires a comprehensive treatment approach. By combining imaging and therapy into a single platform, SCINTIX aims to streamline workflows and enhance clinical outcomes.
Noridian’s reimbursement framework reflects the complexity and innovation of this approach. The contractor has assigned payment rates for the technical components of both the functional modeling procedure and the subsequent treatment sessions. In addition, Noridian has recognized the additional expertise required by physicians by providing reimbursement for the professional component of the modeling procedure. This aspect of the payment structure acknowledges the increased level of clinical involvement and decision-making associated with SCINTIX therapy.
Importantly, the professional component payment also applies to procedures performed in hospital outpatient departments within Noridian’s jurisdictions, further broadening the scope of reimbursement support. This dual-setting applicability ensures that both freestanding centers and hospital-based providers can benefit from the established payment framework, promoting more consistent access to the therapy across different care environments.
The cumulative effect of these reimbursement decisions is expected to accelerate the adoption of SCINTIX therapy across the United States. As more MACs establish favorable payment policies, healthcare providers may be more inclined to invest in the technology, knowing that they can be adequately reimbursed for its use. This, in turn, could lead to increased availability of the therapy for patients, particularly in underserved or rural areas where access to advanced cancer treatments is often limited.
From a broader perspective, the growing support for SCINTIX therapy reflects an ongoing shift in oncology toward more precise, personalized, and technology-driven treatment approaches. Innovations in imaging, data analytics, and automation are enabling new paradigms in cancer care, with the potential to improve outcomes while optimizing resource utilization. Reimbursement policies that align with these advancements are essential for translating technological innovation into real-world clinical practice.
For RefleXion Medical, the latest decision by Noridian represents both validation of its technology and momentum for its commercialization efforts. As the company continues to engage with additional MACs and expand reimbursement coverage, it is likely to focus on generating further clinical and economic evidence to support the value proposition of SCINTIX therapy.
In conclusion, the establishment of reimbursement for SCINTIX autonomous radiotherapy by Noridian Healthcare Solutions marks a pivotal development in the effort to expand access to advanced cancer treatments. By addressing financial barriers and supporting adoption in freestanding centers and hospital settings alike, this decision brings RefleXion Medical closer to its goal of making innovative, precision-driven radiotherapy available to a broader population of patients. As reimbursement coverage continues to grow, SCINTIX therapy may play an increasingly important role in shaping the future of cancer care in the United States.
About RefleXion Medical
RefleXion is a privately held external-beam theranostic oncology company located in Hayward, Calif. It is the first and only company commercializing SCINTIX autonomous radiotherapy, an innovative technology that uses a single radiotracer injection to turn cancer cells into real-time biological beacons to guide treatment delivery. SCINTIX therapy is FDA-cleared for FDG-guided treatment of lung and bone tumors, including metastases. The RefleXion X2 platform is also cleared for conventional image-guided radiotherapy for solid tumors throughout the body.
Source Link:https://www.businesswire.com/
